Director Maha Katabi resigns from Aerovate board and committees effective Oct 6, 2024

Jade Biosciences, Inc.

Maha Katabi, Ph.D., resigned from the board, Audit Committee, and Compensation Committee.
Resignation effective October 6, 2024, voluntary and not due to any disagreement with the company.
Board expressed gratitude for Dr. Katabi's service and contributions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Maha Katabi

Director

JBIO · Jade Biosciences, Inc.

Effective: 2024-10-06
Filed: October 10, 2024, 7:59 PM ET

On October 6, 2024, Maha Katabi, Ph.D., provided notice of her resignation from the board of directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), effective as of October 6, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Maha Katabi resigned as Director at Jade Biosciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 6, 2024, Maha Katabi, Ph.D., provided notice of her resignation from the board of directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), effective as of October 6, 2024.

View on SEC.gov

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-24-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.